Which has better earnings and valuation, IPHA or HOWL?

Innate Pharma has higher revenue and earnings than Werewolf Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innate Pharma $10.19M 16.12 -$55.64M N/A N/A Werewolf Therapeutics $1.88M 25.62 -$60.82M -$0.76 N/A

Is IPHA or HOWL more profitable?

Innate Pharma's return on equity of 0.00% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Innate Pharma N/A N/A N/A Werewolf Therapeutics N/A -166.99% -59.88%

Does the media refer more to HOWL or ORGO?

In the previous week, Organogenesis had 2 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 5 mentions for Organogenesis and 3 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 1.20 beat Organogenesis' score of 0.94 indicating that Werewolf Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Werewolf Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organogenesis 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DTIL or HOWL?

In the previous week, Precision BioSciences had 2 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 5 mentions for Precision BioSciences and 3 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 1.20 beat Precision BioSciences' score of 0.47 indicating that Werewolf Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precision BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Werewolf Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HOWL or BNR?

In the previous week, Werewolf Therapeutics and Werewolf Therapeutics both had 3 articles in the media. Werewolf Therapeutics' average media sentiment score of 1.20 beat Burning Rock Biotech's score of 0.84 indicating that Werewolf Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Werewolf Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Burning Rock Biotech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Werewolf Therapeutics (HOWL) Competitors

$0.99 +0.01 (+0.95%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$1.00 +0.00 (+0.39%)

As of 08:51 AM Eastern

Compare

HOWL vs. IPHA, PRQR, ORGO, DTIL, and BNR

Should you buy Werewolf Therapeutics stock or one of its competitors? Werewolf Therapeutics's main competitors and comparable companies include Innate Pharma (IPHA), ProQR Therapeutics (PRQR), Organogenesis (ORGO), Precision BioSciences (DTIL), and Burning Rock Biotech (BNR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Werewolf Therapeutics compare to Innate Pharma?

Innate Pharma (NASDAQ:IPHA) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Innate Pharma has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

In the previous week, Werewolf Therapeutics had 2 more articles in the media than Innate Pharma. MarketBeat recorded 3 mentions for Werewolf Therapeutics and 1 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 1.41 beat Werewolf Therapeutics' score of 1.20 indicating that Innate Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Innate Pharma	Positive
Werewolf Therapeutics	Positive

Innate Pharma has higher revenue and earnings than Werewolf Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19M	16.12	-$55.64M	N/A	N/A
Werewolf Therapeutics	$1.88M	25.62	-$60.82M	-$0.76	N/A

Innate Pharma presently has a consensus target price of $6.67, indicating a potential upside of 353.51%. Werewolf Therapeutics has a consensus target price of $4.00, indicating a potential upside of 303.59%. Given Innate Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Innate Pharma is more favorable than Werewolf Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Werewolf Therapeutics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

Innate Pharma's return on equity of 0.00% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Werewolf Therapeutics	N/A	-166.99%	-59.88%

0.2% of Innate Pharma shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by company insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Innate Pharma beats Werewolf Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Werewolf Therapeutics compare to ProQR Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Werewolf Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 303.59%. ProQR Therapeutics has a consensus price target of $7.60, suggesting a potential upside of 413.51%. Given ProQR Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe ProQR Therapeutics is more favorable than Werewolf Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Werewolf Therapeutics had 2 more articles in the media than ProQR Therapeutics. MarketBeat recorded 3 mentions for Werewolf Therapeutics and 1 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 1.79 beat Werewolf Therapeutics' score of 1.20 indicating that ProQR Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Werewolf Therapeutics	Positive
ProQR Therapeutics	Very Positive

ProQR Therapeutics has higher revenue and earnings than Werewolf Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	25.62	-$60.82M	-$0.76	N/A
ProQR Therapeutics	$17.99M	8.67	-$47.73M	-$0.46	N/A

Werewolf Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market.

Werewolf Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -223.51%. ProQR Therapeutics' return on equity of -73.83% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-166.99%	-59.88%
ProQR Therapeutics	-223.51%	-73.83%	-35.14%

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

ProQR Therapeutics beats Werewolf Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Werewolf Therapeutics compare to Organogenesis?

Werewolf Therapeutics (NASDAQ:HOWL) and Organogenesis (NASDAQ:ORGO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

Werewolf Therapeutics has a net margin of 0.00% compared to Organogenesis' net margin of -19.94%. Organogenesis' return on equity of -23.89% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-166.99%	-59.88%
Organogenesis	-19.94%	-23.89%	-11.13%

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by insiders. Comparatively, 18.8% of Organogenesis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Werewolf Therapeutics presently has a consensus target price of $4.00, indicating a potential upside of 303.59%. Organogenesis has a consensus target price of $4.33, indicating a potential upside of 258.13%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Werewolf Therapeutics is more favorable than Organogenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Organogenesis had 2 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 5 mentions for Organogenesis and 3 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 1.20 beat Organogenesis' score of 0.94 indicating that Werewolf Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Werewolf Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organogenesis	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organogenesis has higher revenue and earnings than Werewolf Therapeutics. Organogenesis is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	25.62	-$60.82M	-$0.76	N/A
Organogenesis	$564.17M	0.28	$37.03M	-$0.86	N/A

Werewolf Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, Organogenesis has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

Summary

Werewolf Therapeutics beats Organogenesis on 10 of the 16 factors compared between the two stocks.

How does Werewolf Therapeutics compare to Precision BioSciences?

Precision BioSciences (NASDAQ:DTIL) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Precision BioSciences has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market.

38.0% of Precision BioSciences shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 2.7% of Precision BioSciences shares are owned by company insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Werewolf Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Precision BioSciences' return on equity of -72.52% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-72.52%	-32.25%
Werewolf Therapeutics	N/A	-166.99%	-59.88%

Precision BioSciences has higher revenue and earnings than Werewolf Therapeutics. Precision BioSciences is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$34.26M	4.91	-$45.72M	-$2.80	N/A
Werewolf Therapeutics	$1.88M	25.62	-$60.82M	-$0.76	N/A

Precision BioSciences currently has a consensus price target of $32.25, indicating a potential upside of 428.69%. Werewolf Therapeutics has a consensus price target of $4.00, indicating a potential upside of 303.59%. Given Precision BioSciences' stronger consensus rating and higher possible upside, research analysts clearly believe Precision BioSciences is more favorable than Werewolf Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Werewolf Therapeutics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

In the previous week, Precision BioSciences had 2 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 5 mentions for Precision BioSciences and 3 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 1.20 beat Precision BioSciences' score of 0.47 indicating that Werewolf Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precision BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Werewolf Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Precision BioSciences beats Werewolf Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Werewolf Therapeutics compare to Burning Rock Biotech?

Werewolf Therapeutics (NASDAQ:HOWL) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Werewolf Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 303.59%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Werewolf Therapeutics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Werewolf Therapeutics has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -13.60%. Burning Rock Biotech's return on equity of -12.98% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-166.99%	-59.88%
Burning Rock Biotech	-13.60%	-12.98%	-8.59%

Werewolf Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market.

In the previous week, Werewolf Therapeutics and Werewolf Therapeutics both had 3 articles in the media. Werewolf Therapeutics' average media sentiment score of 1.20 beat Burning Rock Biotech's score of 0.84 indicating that Werewolf Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Werewolf Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Burning Rock Biotech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Burning Rock Biotech has higher revenue and earnings than Werewolf Therapeutics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	25.62	-$60.82M	-$0.76	N/A
Burning Rock Biotech	$77.16M	2.05	-$7.92M	-$0.87	N/A

Summary

Werewolf Therapeutics beats Burning Rock Biotech on 10 of the 16 factors compared between the two stocks.

Get Werewolf Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HOWL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HOWL vs. The Competition

Export

Metric	Werewolf Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$47.72M	$3.93B	$7.26B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	-1.30	11.07	204.95	19.81
Price / Sales	25.62	1,148.53	562.00	81.34
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	1.94	17.07	10.75	6.03
Net Income	-$60.82M	-$22.69M	$3.50B	$380.34M
7 Day Performance	7.72%	-4.42%	-2.90%	-2.34%
1 Month Performance	3.47%	-12.47%	-7.37%	-5.31%
1 Year Performance	-40.65%	7.61%	2.97%	-2.94%

Werewolf Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HOWL Werewolf Therapeutics	2.6793 of 5 stars	$0.99 +0.9%	$4.00 +303.6%	-39.2%	$47.72M	$1.88M	N/A	14	News Coverage Positive News
IPHA Innate Pharma	3.4873 of 5 stars	$1.59 +0.6%	$6.67 +319.3%	-23.8%	$177.63M	$4.23M	N/A	163
PRQR ProQR Therapeutics	3.7048 of 5 stars	$1.65 -1.2%	$7.60 +360.6%	-35.4%	$173.85M	$18.36M	N/A	166	Positive News
ORGO Organogenesis	1.9145 of 5 stars	$1.34 +3.9%	$4.33 +223.4%	-69.4%	$172.42M	$454.61M	N/A	854	News Coverage
DTIL Precision BioSciences	3.1614 of 5 stars	$6.20 -1.7%	$32.25 +420.2%	+9.7%	$171.13M	$45.06M	N/A	67

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HOWL) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Werewolf Therapeutics (HOWL) Competitors

HOWL vs. IPHA, PRQR, ORGO, DTIL, and BNR

How does Werewolf Therapeutics compare to Innate Pharma?

Summary

How does Werewolf Therapeutics compare to ProQR Therapeutics?

Summary

How does Werewolf Therapeutics compare to Organogenesis?

Summary

How does Werewolf Therapeutics compare to Precision BioSciences?

Summary

How does Werewolf Therapeutics compare to Burning Rock Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL vs. The Competition

Werewolf Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Werewolf Therapeutics (HOWL) Competitors

HOWL vs. IPHA, PRQR, ORGO, DTIL, and BNR

How does Werewolf Therapeutics compare to Innate Pharma?

Which has more volatility & risk, IPHA or HOWL?

Does the media favor IPHA or HOWL?

Which has better earnings and valuation, IPHA or HOWL?

Do analysts prefer IPHA or HOWL?

Is IPHA or HOWL more profitable?

Do institutionals & insiders believe in IPHA or HOWL?

Summary

How does Werewolf Therapeutics compare to ProQR Therapeutics?

Do analysts recommend HOWL or PRQR?

Does the media prefer HOWL or PRQR?

Which has preferable earnings & valuation, HOWL or PRQR?

Which has more volatility & risk, HOWL or PRQR?

Is HOWL or PRQR more profitable?

Do insiders and institutionals hold more shares of HOWL or PRQR?

Summary

How does Werewolf Therapeutics compare to Organogenesis?

Is HOWL or ORGO more profitable?

Do institutionals and insiders believe in HOWL or ORGO?

Do analysts prefer HOWL or ORGO?

Does the media refer more to HOWL or ORGO?

Which has higher earnings and valuation, HOWL or ORGO?

Which has more volatility and risk, HOWL or ORGO?

Summary

How does Werewolf Therapeutics compare to Precision BioSciences?

Which has more risk and volatility, DTIL or HOWL?

Do insiders & institutionals have more ownership in DTIL or HOWL?

Is DTIL or HOWL more profitable?

Which has higher valuation & earnings, DTIL or HOWL?

Do analysts prefer DTIL or HOWL?

Does the media favor DTIL or HOWL?

Summary

How does Werewolf Therapeutics compare to Burning Rock Biotech?

Do analysts rate HOWL or BNR?

Is HOWL or BNR more profitable?

Which has more risk & volatility, HOWL or BNR?

Does the media prefer HOWL or BNR?

Do institutionals & insiders hold more shares of HOWL or BNR?

Which has higher earnings & valuation, HOWL or BNR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL vs. The Competition

Werewolf Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools